

1 **IgG Antibodies against SARS-CoV-2 Correlate with Days from Symptom Onset, Viral Load and**

2 **IL-10**

3 Mary K. Young<sup>1</sup>, Christine Kornmeier<sup>2</sup>, Rebecca M. Carpenter<sup>1</sup>, Nick R. Natale<sup>3</sup>, Jennifer M.

4 Sasson<sup>1</sup>, Michael D. Solga<sup>4</sup>, Amy J. Mathers<sup>1</sup>, Melinda D. Poulter<sup>6</sup>, Xiao Qiang<sup>2</sup>, William A. Petri

5 Jr.<sup>1,5,6^</sup>

6 <sup>1</sup>Department of Medicine, University of Virginia Health System, Charlottesville, VA, 22908, USA

7 <sup>2</sup>MilliporeSigma, St. Louis, MO, 63103, USA

8 <sup>3</sup>Department of Neuroscience, University of Virginia Health System, Charlottesville, VA, 22908,

9 USA

10 <sup>4</sup>UVA Flow Cytometry Core, University of Virginia, Charlottesville, VA, 22908, USA

11 <sup>5</sup>Department of Microbiology, Immunology and Cancer Biology, University of Virginia Health

12 System, Charlottesville, VA, 22908, USA

13 <sup>6</sup>Department of Pathology, University of Virginia Health System, Charlottesville, VA, 22908, USA

14 <sup>^</sup>Corresponding author

15

16

17

18

19

## 20 **Abstract**

21 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted  
22 in a pandemic of the respiratory disease coronavirus disease 2019 (COVID-19). Antibody testing  
23 is essential to identify persons exposed to the virus and potentially in predicting disease  
24 immunity. 183 COVID-19 patients (68 of whom required mechanical ventilation) and 41 controls  
25 were tested for plasma IgG, IgA and IgM against the SARS-CoV-2 S1, S2, receptor binding  
26 domain (RBD) and N proteins using the MILLIPLEX<sup>®</sup> SARS-CoV-2 Antigen Panel. Plasma cytokines  
27 were concurrently measured using the MILLIPLEX<sup>®</sup> MAP Human Cytokine/Chemokine/Growth  
28 Factor Panel A. As expected the 183 COVID-19 positive patients had high levels of IgG, IgA and  
29 IgM anti-SARS-CoV-2 antibodies against each of the viral proteins. Sensitivity of anti-S1 IgG  
30 increased from 60% to 93% one week after symptom onset. S1-IgG and S1-IgA had specificities  
31 of 98% compared to the 41 COVID-19 negative patients. The 68 ventilated COVID-19 positive  
32 patients had higher antibody levels than the 115 COVID-19 positive patients who were not  
33 ventilated. IgG antibody levels against S1 protein had the strongest positive correlation to days  
34 from symptom onset. There were no statistically significant differences in IgG, IgA and IgM  
35 antibodies against S1 based on age. We found that patients with the highest levels of anti-SARS-  
36 CoV-2 antibodies had the lowest viral load in the nasopharynx. Finally there was a correlation of  
37 high plasma IL-10 with low anti-SARS-CoV-2 antibodies. Anti-SARS-CoV-2 antibody levels, as  
38 measured by a novel antigen panel, increased within days after symptom onset, achieving >  
39 90% sensitivity and specificity within one week, and were highest in patients who required  
40 mechanical ventilation. Antibody levels were inversely associated with viral load but did not

41 differ as a function of age. The correlation of high IL-10 with low antibody response suggests a  
42 potentially suppressive role of this cytokine in the humoral immune response in COVID-19.

43

#### 44 **Introduction**

45 Since its discovery in December 2019, SARS-CoV-2 has caused over 61.8 million cases of COVID-  
46 19 resulting in more than 1.4 million deaths (1). Disease symptoms develop between 2-14 days  
47 after virus exposure and include but are not limited to fever, cough, shortness of breath,  
48 fatigue, new loss of taste or smell, and diarrhea (2). A large proportion of infected individuals  
49 recover from the virus on their own, but some require hospitalization, supplemental oxygen  
50 and mechanical ventilation (2, 3, 4). Little is yet know about long term health effects of COVID-  
51 19 or immunity to reinfection. While polymerase chain reaction (PCR) testing for the virus is an  
52 effective way to diagnosis active infection, antibody testing is critical to identify exposed  
53 individuals and potentially predict disease timepoint and future immunity.

54 SARS-CoV-2 is made up of multiple proteins that the immune system can recognize as antigens.  
55 These proteins include spike protein subunits (S1 and S2), the receptor binding domain (RBD)  
56 that is found on the S1 subunit, and the nucleocapsid protein (N) enclosed in the membrane  
57 allows for determination if an individual has been exposed to the virus even if they were  
58 asymptomatic. However, there are concerns that antibodies from related coronaviruses will  
59 cross react with these tests (6, 7, 8). The relationship between time from infection and antibody  
60 production is not fully delineated nor is it understood why antibody responses have a delayed  
61 onset in some patients. As vaccines are being developed, it is important to understand what  
62 antibody responses are beneficial and promote immunity, and be able to compare antibody

63 responses from people with natural immunity and those who have been vaccinated. The ability  
64 to quantify several antigen specific antibodies by multiplex is a valuable tool in mapping  
65 immune response. Here we describe how IgG, IgA and IgM antibody levels against SARS-CoV-2  
66 antigens measured by the MILLIPLEX® SARS-CoV-2 Antigen Panels relate with disease severity,  
67 age, days from symptom onset, viral burden and plasma IL-10.

68

## 69 **Methods**

70 **Sample Collection and Study Population.** Blood samples from 224 patients tested for SARS-  
71 CoV-2 by PCR between April and September 2020 were collected at the University of Virginia  
72 Medical Center. Clinical information and patient demographics were was obtained from the  
73 electronic medical records and confidentiality was maintained by assigning each patient a  
74 unique identifier. The collection of blood samples and deidentified patient information was  
75 approved by the University of Virginia Institutional Review Board (IRB-HSR #22231 and 200110).  
76 183 of the 224 patients tested were COVID-19 positive and 41 were COVID-19 negative. Of the  
77 COVID-19 positive patients, 70 had two samples from different time points including their first  
78 available blood sample after COVID-19 testing and another 7 to 10 days later. 68 of the COVID-  
79 19 positive patients were placed on mechanical ventilation. Day of symptom onset was  
80 obtained through retrospective chart review of who tested positive for SARS-CoV-2. The start of  
81 patient's symptoms was determined by reviewing the history of present illness from the  
82 electronic medical record. Out of 183 patients reviewed, 2 were asymptomatic for SARS-CoV-2.  
83 Of the remaining 181 patients, day of symptom onset was determined for 112 patients and was  
84 unknown for 69 patients. Nasopharyngeal SARS-CoV-2 cycle threshold (Ct) values were

85 quantified by GeneXpert XVI and GeneXpert Infinity diagnostic systems (Cepheid, Sunnyvale,  
86 CA).

87 **Antibody Detection.** Blood collected in EDTA was centrifuged at 1300 x g for 10 minutes, then  
88 plasma was aliquoted and stored at -80°C until testing. IgG, IgA and IgM antibody levels against  
89 SARS-CoV-2 spike protein subunits S1 and S2, RBD and N were measured in duplicate plasma  
90 samples from the 224 patients using novel MILLIPLEX® SARS-CoV-2 Antigen Panel 1 IgG, SARS-  
91 CoV-2 Antigen Panel 1 IgA and SARS-CoV-2 Antigen Panel 1 IgM (Millipore Sigma, St. Louis, MO,  
92 Catalog Numbers: HC19SERG1-85K, HC19SERA1-85K, and HC19SERM1-85K respectively; For  
93 Research Use Only. Not For Use In Diagnostic Procedures). This panel is designed to measure  
94 antibodies by median fluorescent intensity (MFI). The four antigens are recombinant poly-his-  
95 tagged. Samples were diluted 1:100 in assay buffer. 96-well plates were pre-wetted with 200 µL  
96 wash buffer, covered with plate sealer and incubated for 10 minutes at room temperature with  
97 shaking, then emptied. 25 µL of each diluted sample was added to the sample wells and 25 µL  
98 of assay buffer was added to background wells. 60 µL of both sonicated (30 seconds) and  
99 vortexed (1 minute) analyte and control bead was combined and brought to a final volume of 3  
100 mL with the addition of assay buffer, vortexed, and 25 µL of bead mixture was dispensed into  
101 each plate well. The plate was sealed and incubated for 2 hours at RT with constant shaking. A  
102 handheld magnetic plate washer was used to retain magnetic beads while liquid contents were  
103 discarded appropriately, and wells were washed 3 times with 200 µL wash buffer. 50 µL of  
104 phycoerythrin-anti-human immunoglobulin (IgG, IgA or IgM per kit in use) detection antibody  
105 was added to each well, plate sealed and incubated 90 minutes at RT with constant shaking.  
106 Plates were washed three more times with magnetic plate washer. 150 µL Sheath Fluid was

107 added to each well, the plate was then sealed and shaken at RT for 5 minutes. The plate was  
108 then read on a Luminex<sup>®</sup> MAGPIX<sup>™</sup> Instrument System with a minimum of 50 beads of each  
109 analyte collected per well.

110 **IL-10 Detection.** IL-10 in plasma were measured using the MILLIPLEX<sup>®</sup> MAP Human  
111 Cytokine/Chemokine/Growth Factor Panel A (48 Plex) (Millipore Sigma, St. Louis, MO, Catalog  
112 Number HCYTA-60K-PX48, For Research Use Only. Not For Use In Diagnostic Procedures).

113 **Statistical Methods.** All statistical comparisons and graphs were made using GraphPad Prism 8  
114 software. Mann-Whitney U tests were performed to compare initial antibody levels between  
115 COVID-19 positive and negative groups and different age groups of COVID-19 positive patients.  
116 Sensitivity and specificity were calculated in GraphPad Prism. Simple linear regression and  
117 Spearman correlations were used to associate antibody levels with days from symptom onset in  
118 COVID-19 and assess the relationship between viral load and IgG antibodies that are specific for  
119 SARS-CoV-2 antigens. Patient's with CT values of zero were excluded from analysis. A non-linear  
120 regression analysis with the  $y = \log(x)$  function was performed in R Studio to correlate IL-10  
121 levels from initial samples with IgG levels in ventilated and not ventilated COVID-19 positive  
122 patients (Not Ventilated n=40; Ventilated n = 51). A p value <0.05 was considered statistically  
123 significant.

124

## 125 **Results**

### 126 **Antibody Response to SARS-CoV-2 in COVID-19 Positive and Negative Patients**

127 A total of 224 patients were tested for IgG, IgA and IgM antibodies against SARS-CoV-2 S1, S2,  
128 RBD and N proteins. Of these patients, 183 were positive for COVID-19 and 41 were negative.

129 68 of the COVID-19 positive patients were ventilated and 115 were not. COVID-19 positive  
130 patients had significantly higher antibodies against all SARS-CoV-2 proteins compared to COVID-  
131 19 negative patients (Figure 1, Supplemental Figure 1). Specificity was high for all antigens,  
132 specifically S1-IgG and S1-IgA had specificities of 97.6% and S1-IgM that had a specificity of  
133 92%. IgA antibodies against all antigens were elevated in COVID-19 positive ventilated patients  
134 compared to not ventilated COVID-19 positive patients. IgG antibodies against S1, S2 and RBD  
135 were significantly increased in ventilated patients compared to not ventilated COVID-19  
136 positive patients, and antibodies against N were trending higher in ventilated patients. IgM  
137 antibodies against S1, S2 and N were also significantly higher in ventilated individuals (Figure 1,  
138 Supplemental Figure 1).

#### 139 **Antibody Response to SARS-CoV-2 in COVID-19 Positive Patients and Age**

140 COVID-19 positive patients were divided into 4 age groups (<30, 30-49, 50-69 and >70 years  
141 old) and their antibody levels were compared. There were no statistically significant difference  
142 in IgG, IgA and IgM antibodies against S1 between the different age groups (Figure 2,  
143 Supplemental Figure 2).

#### 144 **Correlation of Antibody Levels and Days from Symptom Onset**

145 Antigen-specific antibodies were analyzed as a function of days from symptom onset  
146 (Supplemental Figure 3a-c). All correlations were statistically significant. IgG antibodies against  
147 S1 were most positively correlated with days from symptom onset with an  $r^2$  value of 0.4030  
148 compared to IgA ( $r^2=0.2142$ ) and IgM ( $r^2=0.2658$ ) antibodies (Figure 3a-c). IgG antibodies  
149 against RBD and S2 followed a similar pattern of correlation as antibodies S1 (Supplemental

150 Figure 3a). Sensitivity also went up after one week from symptom onset. S1-IgG went from  
151 59.6% sensitivity to 92.5%, S1-IgA from 66% to 93.3% and S1-IgM from 68.1% to 95.8%.

### 152 **Correlation of IgG Antibody Levels and Viral Load**

153 IgG antibody levels were correlated to clinical Ct values. IgG antibodies against S1, S2, RBD and  
154 N were found to be positively correlated with Ct values, indicating that patients with lower viral  
155 titers have higher levels of IgG (Figure 4).

### 156 **Correlation of IgG Antibody Levels and Il-10**

157 IgG antibody levels were correlated to Il-10 levels. Anti-S1, S2, RBD and N IgG antibodies were  
158 found to negatively correlate to Il-10 in COVID-19 positive patients who received mechanical  
159 ventilation (Figure 5).

160

### 161 **Discussion**

162 The development of accurate serological testing is critical during the COVID-19 pandemic to  
163 efficiently determine exposure to SARS-CoV-2. Here we demonstrated sensitive and specific  
164 detection of IgG, IgA and IgM antibodies against SARS-CoV-2 antigens S1, S2, RBD in COVID-19  
165 positive patients. There was little apparent cross-reactivity with other related coronaviruses  
166 with the exception of IgG against S2 which showed modest reactivity in COVID-19 (-) patients,  
167 alleviating concerns of false positive antibody tests (7, 8). Additionally, ventilated COVID-19  
168 positive patients had statistically significant higher antibody levels against most antigens  
169 compared to not ventilated COVID-19 positive patients. This confirms similar findings that  
170 individuals with more severe disease have higher antibody levels (9, 10, 11, 12, 13, 14). Further



171 studies need to be done to understand the relationship between increased antibody production  
172 and ventilation.

173 Age has been shown to be the biggest risk factor for more severe disease and death due to  
174 COVID-19. Being over 50 doubles the risk of mortality and over 80 has a 20-fold increase risk of  
175 death (15). Here we have shown there are no significant differences in antibody levels,  
176 suggesting that antibody production does not contribute to age-related mortalities.

177 We were able to determine days from symptom onset for 112 of the 181 COVID-19 positive  
178 patients and of those 45 patients had longitudinal samples 7 to 10 days after their initial  
179 samples. We correlated antibody levels in all of these patient samples with days from symptom  
180 onset. IgG antibodies best correlated with time from symptom onset. IgA and IgM antibodies  
181 did significantly increase over time, but had a weaker correlations compared to IgG. This  
182 suggests that measuring IgG levels can help predict where a patient may be in their disease  
183 course. Sensitivity also went up with time from symptom onset, with all antibodies nearing  
184 100% sensitivity after one week. Other researchers have detected antibodies present as early  
185 as 2-4 days after symptom onset with all patients producing antibodies by 14 days, similar to  
186 what we found (14, 16). Ng et al. found that individuals not infected with SARS-CoV-2,  
187 particularly children and young adults, have anti-S2 antibodies that are linked to other human  
188 coronavirus (17). In Supplemental Figure 3 A, we demonstrate that S2-IgG antibodies are  
189 present in patients as early as the day of symptom onset, suggesting that these antibodies may  
190 be boosted from a previous coronavirus infection. While anti-S2 antibody levels are significantly  
191 higher in patients with COVID-19, there are several patients with no prior SARS-CoV-2 infection  
192 that have these antibodies (Supplemental Figure 1).

193 Studies have indicated that higher SARS-CoV-2 viral burden results in increased disease severity  
194 (18, 19). Here we correlated antibody levels with threshold cycle values (Ct values) from initial  
195 COVID-19 diagnosis and found that IgG antibodies positively correlated with Ct values. This  
196 suggests that patients have higher antibody responses have lower viral burden. Wang et al  
197 found similar results when comparing Ct values to antibody titers (20). These results could  
198 suggest that patients with stronger antibody response are able to clear the infection better.  
199 This may also be indicative of patients being tested further from symptom onset and therefore  
200 having lower viral burden and higher antibody levels. IgG antibodies also negatively correlated  
201 with IL-10 levels. Activation of the IL-10 receptor on B cells has been reported to promote B cell  
202 survival and differentiation into IgM and IgG secreting plasmablasts. The association of high IL-  
203 10 with low antibody responses in ventilated patients is therefore apparently paradoxical, and  
204 worthy of further study (21).

205 To conclude, we found that the MILLIPLEX® SARS-CoV-2 Antigen Panels successfully detected  
206 antigen specific antibodies in patients with COVID-19 and that patients who needed mechanical  
207 ventilation had higher IgG, IgA and IgM antibodies compared to not ventilated patients. While  
208 some antibody levels are lower in patients under 30, we did not see a strong correlation  
209 between age and antibody levels. We did find that IgG better correlates with days from  
210 symptom onset compared to IgA and IgM antibodies. With the approaching availability of  
211 COVID-19 vaccinations, this test would also be beneficial in determining whether a person has  
212 immunity due to natural infection or immunity from vaccination. Vaccinated individuals would  
213 potentially have titers against spike proteins but not the nucleocapsid. These results indicate  
214 the importance of antibody testing to determine disease time point and potential predict

215 disease severity. This multiplex assay will also be beneficial in mapping immune response to  
216 predict potential immunity.

217

218 **Acknowledgements-** We would like to thank Pan Tongvichit, the University of Virginia  
219 Biorepository and Tissue Research Facility, and iTHRIV for their help collecting patient samples  
220 and clinical information. This research was funded by the Manning Family Foundation, the Ivy  
221 Foundation COVID-19 Translational Research Fund and NIH grant R01 AI124214.

222 **Conflicts of Interest-** The authors have no conflicts of interest to report.

223

224

225

226

227

228

229

230

231

232

233

234

235

236

## 237 **References**

- 238 1. WHO Weekly Operational Update on COVID-19, 1 December 2020-  
239 [https://www.who.int/publications/m/item/weekly-epidemiological-update---1-december-](https://www.who.int/publications/m/item/weekly-epidemiological-update---1-december-2020)  
240 2020
- 241 2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A,  
242 Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ,  
243 Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry  
244 J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Godacre B. Factors associated with  
245 COVID-19-related death using OpenSAFELY. *Nature* 584, 430-436 (2020).  
246 <https://doi.org/10.1038/s41586-020-2521-4>
- 247 3. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A,  
248 Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV,  
249 Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lombardy ICU Network. Baseline  
250 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs  
251 of the Lombardy Region, Italy. *JAMA* 323(16):1574-1581 (2020). doi:  
252 [10.1001/jama.2020.5394](https://doi.org/10.1001/jama.2020.5394)
- 253 4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the  
254 Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL,  
255 Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J,  
256 Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio  
257 GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700

- 258 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 323(20):2052-2059  
259 (2020). doi: 10.1001/jama.2020.6775
- 260 5. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS.  
261 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*  
262 367(6483):1260-1263 (2020). doi: 10.1126/science.abb2507.
- 263 6. Ahmed SF, Quadeer AA, McKay MR. Preliminary Identification of Potential Vaccine Targets  
264 for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.  
265 *Viruses* 12 (2020) <https://doi.org/10.3390/v12030254>
- 266 7. Pinto D, Park Y, Beltramello M, Walls AC, Tortorici MA Bianchi S, Jaconi S, Culap K, Zatta F,  
267 De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-  
268 Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D,  
269 Corti D. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV  
270 antibody. *Nature* 583, 290–295 (2020). <https://doi.org/10.1038/s41586-020-2349-y>
- 271 8. Che XY, Qiu LW, Liao ZY, Wang YD, Wen K, Pan YX, Hao W, Mei YB, Cheng VCC, Yuen KY,  
272 Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome—Associated  
273 Coronavirus and Human Coronaviruses 229E and OC43, *The Journal of Infectious Diseases*  
274 191, 2033–2037 (2020). <https://doi.org/10.1086/430355>
- 275 9. Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM,  
276 Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-  
277 Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. Severe Acute  
278 Respiratory Syndrome Coronavirus 2—Specific Antibody Responses in Coronavirus Disease

- 279 Patients. *Emerging Infectious Disease* 26, 1478-1488 (2020).
- 280 <https://doi.org/10.3201/eid2607.200841>
- 281 10. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott  
282 RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R,  
283 Peters B, Greenbaum J, Saphire EO, Smith DM, Sette A, Crotty S. Antigen-Specific Adaptive  
284 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.  
285 *Cell* 183, 1–17 (2020). <https://doi.org/10.1016/j.cell.2020.09.038>
- 286 11. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto A, Fiala B,  
287 Wrenn S, Pettie D, King NP, Greninger AL, Chu HY, Bloom JD. Dynamics of neutralizing  
288 antibody titers in the months after SARS-CoV-2 infection. *Journal of Infectious Disease*.  
289 <https://doi.org/10.1093/infdis/jiaa618>
- 290 12. Amrun SN, Lee CYP, Lee B, Fong SW, Young BE, Chee RSL, Yeo NKW, Torres-Ruesta A,  
291 Carissimo G, Poh CM, Chang ZW, Tay MZ, Chan YH, Chen MIC, Low JGH, Tambyah PA,  
292 Kalimuddin S, Pada S, Tan SY, Sun LJ, Leo YS, Lye DC, Renia L, Ng LFP. Linear B-cell epitopes  
293 in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease  
294 severity. *EBioMedicine* 58: 102911-102919 (2020).  
295 <https://doi.org/10.1016/j.ebiom.2020.102911>
- 296 13. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ, Hu  
297 Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG, Hu L, Zhang XX, Xiang JL,  
298 Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui XP, Zhou Z, Zhu MM, Wang J, Xue CJ, Li XF,  
299 Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ, Zhang Y, Liu XM, Li JJ, Zhang DC, Zhang F,


- 300 Liu P, Yuan J, Li Q, Hu JL, Chen J, Huang AL . Antibody responses to SARS-CoV-2 in patients  
301 with COVID-19. *Nat Med* 26, 845–848 (2020). <https://doi.org/10.1038/s41591-020-0897-1>
- 302 14. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, Feng J, Jia Q, Song Q, Zhu B, Wang J. Immune  
303 Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease  
304 Severity and Outcome for Patients With COVID-19. *Front. Mol. Biosci.* 7, 1-7 (2020).  
305 <https://doi.org/10.3389/fmolb.2020.00157>
- 306 15. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A,  
307 Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ,  
308 Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry  
309 J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Godacre B. Factors associated with  
310 COVID-19-related death using OpenSAFELY. *Nature* 584, 430-436 (2020).  
311 <https://doi.org/10.1038/s41586-020-2521-4>
- 312 16. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ, Hu  
313 Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG, Hu L, Zhang XX, Xiang JL,  
314 Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui XP, Zhou Z, Zhu MM, Wang J, Xue CJ, Li XF,  
315 Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ, Zhang Y, Liu XM, Li JJ, Zhang DC, Zhang F,  
316 Liu P, Yuan J, Li Q, Hu JL, Chen J, Huang AL . Antibody responses to SARS-CoV-2 in patients  
317 with COVID-19. *Nat Med* 26, 845–848 (2020). <https://doi.org/10.1038/s41591-020-0897-1>
- 318 17. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG,  
319 Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson P, Heaney J, Rickman  
320 H, Paraskevopoulou S, Houlihan CF, Thompson K, Sanchez E, Shin GY, Spyer MJ, Joshi D,  
321 O’Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR, Wilkinson M, Marshall LR,

- 322 Rosser EC, Radziszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C,  
323 Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E,  
324 Kassiotis G. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science*  
325 (2020). <https://doi.org/10.1126/science.abe1107>
- 326 18. Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, Goyal P, Safford MM,  
327 Satlin Mj. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of  
328 Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019.  
329 *Clinical Infectious Diseases* ciaa851, (2020). <https://doi.org/10.1093/cid/ciaa851>
- 330 19. Faico-Filho KS, Passarelli VC, Bellei N. Is Higher Viral Load in SARS-CoV-2 Associated with  
331 Death? *The American Society of Tropical Medicine and Hygiene* 103(5), 2019-2021 (2020).  
332 <https://doi.org/10.4269/ajtmh.20-0954>
- 333 20. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, Song T, Alshukairi AN, Chen R, Zhang Z, Gan  
334 M, Zhu A, Huang Y, Luo L, Mok CKP, Gethamy MMA, Tan H, Li Z, Huang X, Li F, Sun J, Zhang  
335 Y, Wen L, Li Y, Chen Z, Zhuang Z, Zhuo J, Chen C, Kuang L, Wang J, Lv H, Jiang Y, Li M, Lin Y,  
336 Deng Y, Tang L, Liang J, Huang J, Perlman S, Zhong N, Zhao J, Peiris JSM, Li Y Zhao J. Kinetics  
337 of viral load and antibody response in relation to COVID-19 severity. *J Clin Invest* 130(10),  
338 5235-5244 (2020). <https://doi.org/10.1172/JCI138759>
- 339 21. Heine G, Drozdenko G, Grün JR, Chang HD, Radbruch A, Worm M. Autocrine IL-10 promotes  
340 human B-cell differentiation into IgM- or IgG-secreting plasmablasts. *Eur J Immunol*. 2014  
341 Jun;44(6):1615-21. doi: 10.1002/eji.201343822. Epub 2014 Mar 11. PMID: 24643722.
- 342
- 343




344 Figures

345 Figure 1.




346

347 Figure 2.




348

349 **Figure 3.**




350

351 **Figure 4.**



352

353 **Figure 5.**



354

355 **Figure 1: IgG, IgA and IgM antibody response to SARS-CoV-2 S1 increased in ventilated**  
 356 **patients.** (a-c) IgG, IgA and IgM antibody responses to SARS-CoV-2 S1 in ventilated COVID-19  
 357 positive patients (n=68), not ventilated COVID-19 positive patients (n=115), and COVID-19  
 358 negative patients (n=41). \*\*\*\*p<0.0001, \*\*\*p<0.001, \*\*p<0.01, \*p<0.05

359 **Figure 2: IgG, IgA and IgM antibody response to SARS-CoV-2 S1 and age.** (a-c) IgG, IgA and IgM  
 360 antibody responses to SARS-CoV-2 S1 in patients less than 30 years old (n=12), 30-49 years old  
 361 (n=53), 50-69 years old (n=70) and greater than 70 years old (n=47).

362 **Figure 3: Correlation of IgG, IgA and IgM antibodies against SARS-CoV-2 S1 and days from**  
 363 **symptom onset.** (a-c) Correlation of IgG, IgA and IgM antibodies against SARS-CoV-2 S1 and  
 364 days from symptom onset (168 samples from 123 patients).

365 **Figure 4: Correlation of IgG Antibodies and SARS-CoV-2 Ct Value.** (a-d) Correlation of IgG  
 366 antibodies against SARS-CoV-2 S1, S2, RBD and N and SARS-CoV-2 Ct Value (n=50).

367 **Figure 5: Correlation of IgG Antibodies and IL-10.** (a-d) Correlation of anti-S1, S2, RBD and N IgG  
368 antibodies and IL-10 in ventilated (black, n=51) and not ventilated (grey, n=40) COVID-19  
369 positive patients.

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388